Exelixis, Inc (EXEL) is a leading biotechnology business based in the US. It opened the day at $18.03 after a previous close of $17.83. During the day the price has varied from a low of $17.87 to a high of $18.32. The latest price was $18.01 (25 minute delay). Exelixis is listed on the NASDAQ and employs 773 staff. All prices are listed in US Dollars.
How to buy shares in Exelixis
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EXEL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Exelixis stock price (NASDAQ: EXEL)Use our graph to track the performance of EXEL stocks over time.
Exelixis shares at a glance
|52-week range||$16.24 - $27.35|
|50-day moving average||$20.21|
|200-day moving average||$22.42|
|Wall St. target price||$29.93|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.21|
Buy Exelixis shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Exelixis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Exelixis price performance over time
|1 week (2021-07-14)||N/A|
|1 month (2021-06-25)||-23.10%|
|3 months (2021-04-21)||N/A|
|6 months (2021-01-21)||N/A|
|1 year (2020-07-21)||N/A|
|2 years (2019-07-21)||N/A|
|3 years (2018-07-21)||N/A|
|5 years (2016-07-21)||N/A|
Is Exelixis under- or over-valued?
Valuing Exelixis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exelixis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Exelixis's P/E ratio
Exelixis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 83x. In other words, Exelixis shares trade at around 83x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Exelixis's PEG ratio
Exelixis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0902. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Exelixis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Exelixis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $65.5 million.
The EBITDA is a measure of a Exelixis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1 billion|
|Operating margin TTM||5.37%|
|Gross profit TTM||$954 million|
|Return on assets TTM||1.67%|
|Return on equity TTM||3.54%|
|Market capitalisation||$5.3 billion|
TTM: trailing 12 months
Shorting Exelixis shares
There are currently 12.1 million Exelixis shares held short by investors – that's known as Exelixis's "short interest". This figure is 6% up from 11.4 million last month.
There are a few different ways that this level of interest in shorting Exelixis shares can be evaluated.
Exelixis's "short interest ratio" (SIR)
Exelixis's "short interest ratio" (SIR) is the quantity of Exelixis shares currently shorted divided by the average quantity of Exelixis shares traded daily (recently around 2.6 million). Exelixis's SIR currently stands at 4.61. In other words for every 100,000 Exelixis shares traded daily on the market, roughly 4610 shares are currently held short.
However Exelixis's short interest can also be evaluated against the total number of Exelixis shares, or, against the total number of tradable Exelixis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exelixis's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Exelixis shares in existence, roughly 40 shares are currently held short) or 0.042% of the tradable shares (for every 100,000 tradable Exelixis shares, roughly 42 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Exelixis.
Find out more about how you can short Exelixis stock.
Exelixis share dividends
We're not expecting Exelixis to pay a dividend over the next 12 months.
Exelixis share price volatility
Over the last 12 months, Exelixis's shares have ranged in value from as little as $16.24 up to $27.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exelixis's is 1.0577. This would suggest that Exelixis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Exelixis, Inc. , an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer.
Stocks similar to Exelixis
Exelixis in the news
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
4 Biotech Stocks That Could Be Bargains
Frequently asked questionsWhat percentage of Exelixis is owned by insiders or institutions?
Currently 2.173% of Exelixis shares are held by insiders and 84.82% by institutions. How many people work for Exelixis?
Latest data suggests 773 work at Exelixis. When does the fiscal year end for Exelixis?
Exelixis's fiscal year ends in January. Where is Exelixis based?
Exelixis's address is: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 What is Exelixis's ISIN number?
Exelixis's international securities identification number is: US30161Q1040 What is Exelixis's CUSIP number?
Exelixis's Committee on Uniform Securities Identification Procedures number is: 30161Q104
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert